Greenwood Capital Associates LLC Invests $5.35 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Greenwood Capital Associates LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 8,442 shares of the biopharmaceutical company’s stock, valued at approximately $5,354,000.

A number of other institutional investors also recently modified their holdings of the company. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $25,000. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the period. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $28,000. Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $36,000. Finally, Crowley Wealth Management Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $36,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $518.60 on Thursday. The business’s fifty day moving average price is $564.76 and its 200-day moving average price is $653.10. The stock has a market capitalization of $55.99 billion, a price-to-earnings ratio of 13.55, a PEG ratio of 2.34 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. During the same quarter last year, the company earned $9.55 earnings per share. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.68%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on REGN. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $700.00 to $580.00 in a report on Friday, May 30th. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, The Goldman Sachs Group decreased their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.